Key result
ICDs remain the cornerstone therapy to prevent sudden cardiac death in Brugada syndrome.
Why the study?
Brugada syndrome is a rare arrhythmogenic disease with a high risk of sudden cardiac arrest and limited consolidated clinical knowledge.
Affirms ICDs as key therapy to prevent SCD in Brugada syndrome; leaves open refined risk models incorporating age, sex, and syncope.
Brugada syndrome (BrS) is a rare disease in which arrhythmogenic changes occur in patients without any structural heart pathology. Its most dangerous complication is sudden cardiac arrest, which most often occurs around the 3rd and 4th decade of life of patients. In a similar period of time (20 - 40 years of age), the first clinical manifestations of the disease also most often occur, although this can happen even sooner in the case of a malignant form of the disease. Brugada syndrome is significantly (about 8 times) more frequently diagnosed in men, and the main factors that strongly worsen its prognosis are incidents of syncope noted in the patient's history and observed spontaneous changes in ECG studies [1][2].
No takes yet. Share an insight, caveat, or question.
Kłakowicz et al. (2023) conducted a review in Brugada syndrome. Brugada syndrome is a rare genetic channelopathy diagnosed by type 1 ECG changes, with implantable cardioverter-defibrillators serving as the most important therapy to prevent sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: